David S Goldstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128990/publications.pdf Version: 2024-02-01

		3721	4323
424	37,505	89	173
papers	citations	h-index	g-index
431	431	431	38483
all docs	docs citations	times ranked	citing authors
431 all docs	431 docs citations	431 times ranked	38483 citing authors

#	Article	lF	CITATIONS
1	The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	8
2	Research Opportunities in Autonomic Neural Mechanisms of CardiopulmonaryÂRegulation. JACC Basic To Translational Science, 2022, 7, 265-293.	1.9	17
3	What new can we learn from cardiac sympathetic neuroimaging in synucleinopathies?. Clinical Autonomic Research, 2022, 32, 95-98.	1.4	4
4	Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study. Translational Neurodegeneration, 2022, 11, 15.	3.6	12
5	Sex-Specific Alterations in Dopamine Metabolism in the Brain after Methamphetamine Self-Administration. International Journal of Molecular Sciences, 2022, 23, 4353.	1.8	6
6	Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases. Journal of the American Heart Association, 2022, 11, .	1.6	4
7	The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm, 2021, 18, 508-509.	0.3	109
8	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
9	Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases?. Clinical Autonomic Research, 2021, 31, 543-551.	1.4	5
10	Cardiac <scp>¹⁸Fâ€Dopamine PET</scp> Distinguishes <scp>PD</scp> with Orthostatic Hypotension from Parkinsonian <scp>MSA</scp> . Movement Disorders Clinical Practice, 2021, 8, 582-586.	0.8	15
11	Evidence of Reduced Efferent Renal Sympathetic Innervation After Chemical Renal Denervation in Humans. American Journal of Hypertension, 2021, 34, 744-752.	1.0	7
12	Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension. Clinical Autonomic Research, 2021, 31, 351-353.	1.4	1
13	Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. Journal of Neurochemistry, 2021, 158, 554-568.	2.1	14
14	Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. Journal of Neurochemistry, 2021, 158, 960-979.	2.1	22
15	The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. International Journal of Molecular Sciences, 2021, 22, 5999.	1.8	20
16	<scp>αâ€5ynuclein</scp> Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. Movement Disorders, 2021, 36, 2346-2357.	2.2	11
17	Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 253-259.	1.3	4
18	Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102828.	1.4	113

#	Article	IF	CITATIONS
19	Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting – Part 2. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102836.	1.4	30
20	Multiple catechols in human plasma after drinking caffeinated or decaffeinated coffee. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122988.	1.2	3
21	Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies. Clinical Autonomic Research, 2021, 31, 677-684.	1.4	8
22	Stress and the "extended―autonomic system. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102889.	1.4	20
23	Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clinical Autonomic Research, 2020, 30, 13-18.	1.4	15
24	Response to: Human papillomavirus (HPV) vaccine safety concerning POTS, CRPS and related conditions. Clinical Autonomic Research, 2020, 30, 183-184.	1.4	1
25	The catecholaldehyde hypothesis: where MAO fits in. Journal of Neural Transmission, 2020, 127, 169-177.	1.4	35
26	Cardiac sympathetic innervation and vesicular storage in pure autonomic failure. Annals of Clinical and Translational Neurology, 2020, 7, 1908-1918.	1.7	9
27	The extended autonomic system, dyshomeostasis, and COVID-19. Clinical Autonomic Research, 2020, 30, 299-315.	1.4	93
28	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	0.8	31
29	The "Sick-but-not-Dead―Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. Seminars in Neurology, 2020, 40, 502-514.	0.5	13
30	Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Annals of Clinical and Translational Neurology, 2020, 7, 2450-2460.	1.7	16
31	"Sick-but-not-deadâ€+ multiple paths to catecholamine deficiency in Lewy body diseases. Stress, 2020, 23, 633-637.	0.8	5
32	Dopamine-Related Measurements From Both IPSC-Derived Dopaminergic Neurons and [18F]-FDOPA PET in Patients With Gaucher Disease With and Without Parkinsonism. Biological Psychiatry, 2020, 87, S164.	0.7	0
33	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	13.7	6,140
34	3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing <i>α</i> -Synuclein. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 157-165.	1.3	30
35	Mechanisms of Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006331.	1.6	52
36	Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction. PLoS Genetics, 2020, 16, e1008868.	1.5	12

#	Article	IF	CITATIONS
37	Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Autonomic Neuroscience: Basic and Clinical, 2020, 223, 102550.	1.4	6
38	How does homeostasis happen? Integrative physiological, systems biological, and evolutionary perspectives. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 316, R301-R317.	0.9	43
39	Association of innervation-adjusted alpha-synuclein in arrector pili muscles with cardiac noradrenergic deficiency in autonomic synucleinopathies. Clinical Autonomic Research, 2019, 29, 587-593.	1.4	8
40	Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. Neurology, 2019, 92, 1113-1115.	1.5	14
41	Thirty-Day Readmission Risk Model for Older Adults Hospitalized With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005320.	0.9	40
42	Autonomic uprising: the tilt table test in autonomic medicine. Clinical Autonomic Research, 2019, 29, 215-230.	1.4	68
43	Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension. Hypertension, 2019, 73, 910-918.	1.3	28
44	Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism and Related Disorders, 2019, 67, 27-33.	1.1	21
45	Substantial renal conversion of l-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Clinical Autonomic Research, 2019, 29, 113-117.	1.4	6
46	The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Research, 2019, 1702, 74-84.	1.1	45
47	Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCl Insight, 2019, 4, .	2.3	22
48	Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 108-112.	1.1	40
49	Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure. Clinical Autonomic Research, 2018, 28, 223-230.	1.4	15
50	Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Annals of Neurology, 2018, 83, 522-531.	2.8	150
51	The physical examination as a window into autonomic disorders. Clinical Autonomic Research, 2018, 28, 23-33.	1.4	19
52	3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by <i>N</i> -Acetylcysteine. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 113-124.	1.3	34
53	Roles of catechol neurochemistry in autonomic function testing. Clinical Autonomic Research, 2018, 28, 273-288.	1.4	24
54	Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky. Cellular and Molecular Neurobiology, 2018, 38, 13-24.	1.7	26

#	Article	IF	CITATIONS
55	Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism and Related Disorders, 2018, 52, 90-93.	1.1	34
56	Plasma Catechols After Eating Olives. Clinical and Translational Science, 2018, 11, 32-37.	1.5	2
57	Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model. Brain Research, 2018, 1679, 155-170.	1.1	14
58	Roles of cardiac sympathetic neuroimaging in autonomic medicine. Clinical Autonomic Research, 2018, 28, 397-410.	1.4	17
59	Natural history of pure autonomic failure: A <scp>U</scp> nited <scp>S</scp> tates prospective cohort. Annals of Neurology, 2017, 81, 287-297.	2.8	229
60	Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2017, 35, 88-91.	1.1	26
61	Pure autonomic failure without synucleinopathy. Clinical Autonomic Research, 2017, 27, 97-101.	1.4	21
62	The autonomic medical history. Clinical Autonomic Research, 2017, 27, 223-233.	1.4	24
63	Autonomic function tests: introduction to the series. Clinical Autonomic Research, 2017, 27, 141-143.	1.4	2
64	Is pure autonomic failure a distinct nosologic entity?. Clinical Autonomic Research, 2017, 27, 121-122.	1.4	2
65	Beat-to-beat blood pressure and heart rate responses to the Valsalva maneuver. Clinical Autonomic Research, 2017, 27, 361-367.	1.4	55
66	N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochemical Research, 2017, 42, 3289-3295.	1.6	24
67	Homeostatic systems, biocybernetics, and autonomic neuroscience. Autonomic Neuroscience: Basic and Clinical, 2017, 208, 15-28.	1.4	37
68	Autoimmunity-associated autonomic failure with sympathetic denervation. Clinical Autonomic Research, 2017, 27, 57-62.	1.4	16
69	Irwin J Kopin. Neuropsychopharmacology, 2017, 42, 2656-2656.	2.8	1
70	3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochemical Research, 2016, 41, 2173-2178.	1.6	46
71	Systemic hemodynamics during orthostasis in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 25, 106-107.	1.1	3
72	Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo. Cell and Tissue Research, 2016, 363, 693-712.	1.5	43

#	Article	IF	CITATIONS
73	Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. Parkinsonism and Related Disorders, 2016, 31, 79-86.	1.1	27
74	Cardiac Dysautonomia and Survival in Hereditary Transthyretin Amyloidosis â^—. JACC: Cardiovascular Imaging, 2016, 9, 1442-1445.	2.3	18
75	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
76	DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. Autonomic Neuroscience: Basic and Clinical, 2016, 194, 46-51.	1.4	18
77	Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 484-493.	1.3	37
78	Sympathoneural and Adrenomedullary Responses to Mental Stress. , 2015, 5, 119-146.		63
79	197. Survival, Growth, and Neurobehavioral Outcomes in a Mouse Model of Menkes Disease With CSF-Directed AAV9 and Subcutaneous Copper Histidine. Molecular Therapy, 2015, 23, S78.	3.7	ο
80	The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein. Neuroscience Letters, 2015, 590, 134-137.	1.0	15
81	Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2015, 133, 14-25.	2.1	34
82	Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. Clinical Autonomic Research, 2015, 25, 61-67.	1.4	9
83	Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism and Related Disorders, 2015, 21, 1013-1022.	1.1	30
84	Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 1345-1352.	2.9	27
85	Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism and Related Disorders, 2015, 21, 567-572.	1.1	20
86	Survival in synucleinopathies. Neurology, 2015, 85, 1554-1561.	1.5	84
87	Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9977-9982.	3.3	160
88	Molecular and biochemical characterization of Mottled-dappled, an embryonic lethal Menkes disease mouse model. Molecular Genetics and Metabolism, 2014, 113, 294-300.	0.5	4
89	Carotid artery thickening and neurocirculatory abnormalities in de novo Parkinson disease. Journal of Neural Transmission, 2014, 121, 1259-1268.	1.4	10

90 Dysautonomia in Parkinson Disease. , 2014, 4, 805-826.

120

#	Article	IF	CITATIONS
91	Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neuroscience Letters, 2014, 569, 27-32.	1.0	59
92	A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 219-228.	2.1	27
93	Benomyl, Aldehyde Dehydrogenase, DOPAL, and the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease. Chemical Research in Toxicology, 2014, 27, 1359-1361.	1.7	55
94	Quantitative indices of baroreflex-sympathoneural function: application to patients with chronic autonomic failure. Clinical Autonomic Research, 2014, 24, 103-110.	1.4	12
95	Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology, 2014, 76, 97-105.	2.0	58
96	Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. , 2014, 144, 268-282.		129
97	Cardiac Sympathetic Denervation. , 2014, , 133.		0
98	Autonomic dysfunction in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 259-278.	1.0	76
99	Differential responses of components of the autonomic nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 13-22.	1.0	39
100	Sympathetic neuroimaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 365-370.	1.0	22
101	Concepts of Scientific Integrative Medicine Applied to the Physiology and Pathophysiology of Catecholamine Systems. , 2013, 3, 1569-1610.		27
102	Biomarkers, Mechanisms, and Potential Prevention of Catecholamine Neuron Loss in Parkinson Disease. Advances in Pharmacology, 2013, 68, 235-272.	1.2	28
103	Cardiovascular Autonomic Dysfunction in Parkinson's Disease. , 2013, , 201-212.		4
104	Determinants of buildup of the toxic dopamine metabolite <scp>DOPAL</scp> in Parkinson's disease. Journal of Neurochemistry, 2013, 126, 591-603.	2.1	169
105	Lâ€Threoâ€Dihydroxyphenylserine corrects neurochemical abnormalities in a menkes disease mouse model. Annals of Neurology, 2013, 73, 259-265.	2.8	12
106	Phosphorylated α-Synuclein in Parkinson's Disease. Science Translational Medicine, 2012, 4, 121ra20.	5.8	223
107	Neurocardiology: Therapeutic Implications for Cardiovascular Disease. Cardiovascular Therapeutics, 2012, 30, e89-106.	1.1	16
108	In utero copper treatment for Menkes disease associated with a severe ATP7A mutation. Molecular Genetics and Metabolism, 2012, 107, 222-228.	0.5	23

#	Article	IF	CITATIONS
109	Temporary elimination of orthostatic hypotension by norepinephrine infusion. Clinical Autonomic Research, 2012, 22, 303-306.	1.4	7
110	Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology, 2012, 79, 1323-1331.	1.5	121
111	Vesicular uptake blockade generates the toxic dopamine metabolite 3,4â€dihydroxyphenylacetaldehyde in <scp>PC</scp> 12 cells: relevance to the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2012, 123, 932-943.	2.1	65
112	Noradrenergic Neurotransmission. , 2012, , 37-43.		1
113	Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain, 2012, 135, 1900-1913.	3.7	115
114	Conditional Expression of Parkinson's Disease-Related Mutant Â-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1. Journal of Neuroscience, 2012, 32, 9248-9264.	1.7	165
115	Stress, Allostatic Load, Catecholamines, and Other Neurotransmitters in Neurodegenerative Diseases. Cellular and Molecular Neurobiology, 2012, 32, 661-666.	1.7	18
116	Adrenomedullary Response to Glucagon in Patients with Primary Sjögren's Syndrome. Cellular and Molecular Neurobiology, 2012, 32, 903-906.	1.7	7
117	Cardiac Sympathetic Neuroimaging in Dementia with Lewy Bodies. Journal of Neuroimaging, 2012, 22, 109-110.	1.0	4
118	Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiology of Disease, 2012, 46, 572-580.	2.1	227
119	What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy. Neurobiology of Disease, 2012, 46, 505-507.	2.1	12
120	Circadian rhythms in executive function during the transition to adolescence: the effect of synchrony between chronotype and time of day. Developmental Science, 2012, 15, 408-416.	1.3	88
121	Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clinical Autonomic Research, 2012, 22, 57-61.	1.4	33
122	Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease. PLoS ONE, 2012, 7, e31522.	1.1	142
123	Clinical Sympathetic Imaging. , 2012, , 399-403.		Ο
124	Autonomic dysfunction in PD: A window to early detection?. Journal of the Neurological Sciences, 2011, 310, 118-122.	0.3	64
125	Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. Journal of the Neurological Sciences, 2011, 310, 123-128.	0.3	99
126	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	1.9	97

#	Article	IF	CITATIONS
127	Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Autonomic Neuroscience: Basic and Clinical, 2011, 161, 46-48.	1.4	470
128	Prevalence of orthostatic hypotension in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2011, 17, 724-729.	1.1	259
129	Diagnosis of Copper Transport Disorders. , 2011, Chapter 17, Unit17.9.		10
130	Catechols in post-mortem brain of patients with Parkinson disease. European Journal of Neurology, 2011, 18, 703-710.	1.7	111
131	Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. Experimental Physiology, 2011, 96, 1255-1261.	0.9	623
132	Patients as a Scientific Resource: Comments on Receiving the Ahrens Award. Clinical and Translational Science, 2011, 4, 231-232.	1.5	0
133	Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Clinical Autonomic Research, 2011, 21, 133-141.	1.4	292
134	Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research, 2011, 21, 69-72.	1.4	1,231
135	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580.	2.8	371
136	Effects of Carbidopa and Entacapone on the Metabolic Fate of the Norepinephrine Prodrug L-DOPS. Journal of Clinical Pharmacology, 2011, 51, 66-74.	1.0	25
137	ATP7A Gene Addition to the Choroid Plexus Results in Long-term Rescue of the Lethal Copper Transport Defect in a Menkes Disease Mouse Model. Molecular Therapy, 2011, 19, 2114-2123.	3.7	64
138	Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. Journal of Clinical Investigation, 2011, 121, 3320-3330.	3.9	64
139	Cardiac ectopy in chronic autonomic failure. Clinical Autonomic Research, 2010, 20, 85-92.	1.4	17
140	Catecholamines 101. Clinical Autonomic Research, 2010, 20, 331-352.	1.4	80
141	Adrenal Responses to Stress. Cellular and Molecular Neurobiology, 2010, 30, 1433-1440.	1.7	176
142	Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde. Clinical Chemistry, 2010, 56, 832-838.	1.5	11
143	Association of anosmia with autonomic failure in Parkinson disease. Neurology, 2010, 74, 245-251.	1.5	56
144	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27

#	Article	IF	CITATIONS
145	Pure autonomic failure. Neurology, 2010, 74, 536-537.	1.5	38
146	Neuroscience and heart-brain medicine: The year in review. Cleveland Clinic Journal of Medicine, 2010, 77, S34-S39.	0.6	16
147	Simultaneous Liquid-Chromatographic Determination of Plasma Catecholamines and Metabolites. Clinical Chemistry, 2009, 55, 2223-2224.	1.5	4
148	Hypertension Increases Cerebral 6- ¹⁸ F-Fluorodopa–Derived Radioactivity. Journal of Nuclear Medicine, 2009, 50, 1479-1482.	2.8	3
149	Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clinical Autonomic Research, 2009, 19, 259-262.	1.4	34
150	Relative Efficiencies of Plasma Catechol Levels and Ratios for Neonatal Diagnosis of Menkes Disease. Neurochemical Research, 2009, 34, 1464-1468.	1.6	44
151	Neurogenic Orthostatic Hypotension. Circulation, 2009, 119, 139-146.	1.6	154
152	Clinical laboratory evaluation of autoimmune autonomic ganglionopathy: Preliminary observations. Autonomic Neuroscience: Basic and Clinical, 2009, 146, 18-21.	1.4	25
153	Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism and Related Disorders, 2009, 15, 122-127.	1.1	39
154	Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism and Related Disorders, 2009, 15, 516-520.	1.1	59
155	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Cleveland Clinic Journal of Medicine, 2009, 76, S47-S50.	0.6	23
156	Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Cleveland Clinic Journal of Medicine, 2009, 76, S51-S59.	0.6	41
157	Pioneer Award Address: Ignorance isn't biased: Comments on receiving the Pioneer Award. Cleveland Clinic Journal of Medicine, 2009, 76, S31-S36.	0.6	0
158	Plasma Catechols in Familial Dysautonomia: A Long-term Follow-up Study. Neurochemical Research, 2008, 33, 1889-1893.	1.6	13
159	Central dopamine deficiency in pure autonomic failure. Clinical Autonomic Research, 2008, 18, 58-65.	1.4	36
160	Cardiac sympathetic hypo-innervation in familial dysautonomia. Clinical Autonomic Research, 2008, 18, 115-119.	1.4	21
161	Generalized and neurotransmitterâ€selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Movement Disorders, 2008, 23, 1725-1732	2.2	68
162	Seeing the glass half full: Optimistic expressive writing improves mental health among chronically stressed caregivers. British Journal of Health Psychology, 2008, 13, 73-76.	1.9	21

#	Article	IF	CITATIONS
163	Computer Models of Stress, Allostasis, and Acute and Chronic Diseases. Annals of the New York Academy of Sciences, 2008, 1148, 223-231.	1.8	25
164	Attenuated Preâ€ejection Period Response to Tyramine in Patients with Cardiac Sympathetic Denervation. Annals of the New York Academy of Sciences, 2008, 1148, 486-489.	1.8	15
165	Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism and Related Disorders, 2008, 14, 600-607.	1.1	135
166	Neuronal Source of Plasma Dopamine. Clinical Chemistry, 2008, 54, 1864-1871.	1.5	74
167	Takotsubo Cardiomyopathy. Circulation, 2008, 118, 2754-2762.	1.6	735
168	Genotype and Vascular Phenotype Linked by Catecholamine Systems. Circulation, 2008, 117, 458-461.	1.6	4
169	Neonatal Diagnosis and Treatment of Menkes Disease. New England Journal of Medicine, 2008, 358, 605-614.	13.9	269
170	Age differences in choice satisfaction: A positivity effect in decision making Psychology and Aging, 2008, 23, 33-38.	1.4	61
171	Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis. Endocrine Regulations, 2008, 42, 111-9.	0.5	118
172	Does Expressive Writing Reduce Stress and Improve Health for Family Caregivers of Older Adults?. Gerontologist, The, 2007, 47, 296-306.	2.3	33
173	Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. Journal of Medical Genetics, 2007, 44, 492-497.	1.5	40
174	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel–Lindau syndrome. Journal of Endocrinology, 2007, 193, 225-233.	1.2	14
175	CLINICAL EVALUATION OF THE AUTONOMIC NERVOUS SYSTEM. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 33-49.	0.4	3
176	AUTONOMIC FAILURE IN NEURODEGENERATIVE DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 111-142.	0.4	4
177	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. Journal of Hypertension, 2007, 25, 2286-2295.	0.3	42
178	Autonomic dysfunction in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 343-363.	1.0	7
179	Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Heart Rhythm, 2007, 4, 1523-1529.	0.3	175
180	Evolution of concepts of stress. Stress, 2007, 10, 109-120.	0.8	244

#	Article	IF	CITATIONS
181	Time of day, intellectual performance, and behavioral problems in Morning versus Evening type adolescents: Is there a synchrony effect?. Personality and Individual Differences, 2007, 42, 431-440.	1.6	225
182	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research, 2007, 17, 118-121.	1.4	88
183	Cardiac denervation in patients with Parkinson disease Cleveland Clinic Journal of Medicine, 2007, 74, S91-S91.	0.6	61
184	Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release and neurocardiogenic syncope. Clinical Science, 2006, 111, 209-216.	1.8	14
185	Neuropharmacologic Distinction of Neurogenic Orthostatic Hypotension Syndromes. Clinical Neuropharmacology, 2006, 29, 97-105.	0.2	33
186	L-Dihydroxyphenylserine (L-DOPS): A Norepinephrine Prodrug. Cardiovascular Drug Reviews, 2006, 24, 189-203.	4.4	87
187	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	1.8	24
188	Clinical Catecholamine Neurochemistry: A Legacy of Julius Axelrod. Cellular and Molecular Neurobiology, 2006, 26, 693-700.	1.7	13
189	Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia. Clinical Autonomic Research, 2006, 16, 40-45.	1.4	28
190	Orthostatic hypotension as an early finding in Parkinson's disease. Clinical Autonomic Research, 2006, 16, 46-54.	1.4	176
191	Coronary vascular resistance in primary chronic autonomic failure. Clinical Autonomic Research, 2006, 16, 293-295.	1.4	2
192	Prevalence of anti-locus coeruleus immunoreactivity in CSF of patients with autonomic failure. Clinical Autonomic Research, 2006, 16, 401-405.	1.4	1
193	INTRODUCTION TO THE SALSA, A SALTDOME SHOWER ARRAY AS A GZK NEUTRINO OBSERVATORY. International Journal of Modern Physics A, 2006, 21, 252-253.	0.5	0
194	Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model*. Critical Care Medicine, 2005, 33, 1311-1316.	0.4	99
195	Cardiovascular Autonomic Dysfunction. , 2005, , 149-157.		4
196	Neurocirculatory Abnormalities in Parkinson Disease With Orthostatic Hypotension. Hypertension, 2005, 46, 1333-1339.	1.3	123
197	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
198	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2068-2075.	1.8	213

#	Article	IF	CITATIONS
199	Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8303-8308.	3.3	90
200	Dopamine Contamination of Infused Tyramine. Clinical Chemistry, 2005, 51, 1733-1735.	1.5	11
201	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 2005, 153, 551-563.	1.9	57
202	Neurocirculatory Abnormalities in Chronic Orthostatic Intolerance. Circulation, 2005, 111, 839-845.	1.6	36
203	Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm, 2005, 2, 602-609.	0.3	18
204	Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. Journal of Nuclear Medicine, 2005, 46, 1775-81.	2.8	60
205	Painful sweating. Neurology, 2004, 63, 1471-1475.	1.5	11
206	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
207	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. Hypertension, 2004, 43, 1227-1232.	1.3	15
208	Diagnosis and Localization of Pheochromocytoma. Hypertension, 2004, 43, 907-910.	1.3	40
209	Association between cardiac denervation and parkinsonism caused by αâ€synuclein gene triplication. Brain, 2004, 127, 768-772.	3.7	131
210	Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism?. Annals of the New York Academy of Sciences, 2004, 1018, 224-230.	1.8	49
211	Functional Neuroimaging of Sympathetic Innervation of the Heart. Annals of the New York Academy of Sciences, 2004, 1018, 231-243.	1.8	15
212	Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clinical Autonomic Research, 2004, 14, 363-368.	1.4	47
213	Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology, 2004, 176, 369-375.	1.5	11
214	Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 480-489.	2.3	13
215	Coexpression of Tyrosine Hydroxylase, GTP Cyclohydrolase I, Aromatic Amino Acid Decarboxylase, and Vesicular Monoamine Transporter 2 from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector Supports High-Level, Long-Term Biochemical and Behavioral Correction of a Rat Model of Parkinson's Disease, Human Gene Therapy, 2004, 15, 1177-1196.	1.4	74
216	Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 2004, 56, 331-349.	7.1	849

#	Article	IF	CITATIONS
217	Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor. Endocrine Pathology, 2003, 14, 193-212.	5.2	61
218	Hereditary dysautonomias: current knowledge and collaborations for the future. Clinical Autonomic Research, 2003, 13, 180-195.	1.4	2
219	Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurology, The, 2003, 2, 669-676.	4.9	292
220	Sympathoadrenal imbalance before neurocardiogenic syncope. American Journal of Cardiology, 2003, 91, 53-58.	0.7	64
221	Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 800-811.	1.3	355
222	Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension. Circulation, 2003, 108, 724-728.	1.6	169
223	Baroreflex Failure as a Late Sequela of Neck Irradiation. Hypertension, 2003, 42, 110-116.	1.3	105
224	Association Between Supine Hypertension and Orthostatic Hypotension in Autonomic Failure. Hypertension, 2003, 42, 136-142.	1.3	203
225	Correction of a Rat Model of Parkinson's Disease by Coexpression of Tyrosine Hydroxylase and Aromatic Amino Acid Decarboxylase from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector. Human Gene Therapy, 2003, 14, 415-424.	1.4	62
226	Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 855-860.	1.3	34
227	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	1.8	447
228	Imaging of the Autonomic Nervous System: Focus on Cardiac Sympathetic Innervation. Seminars in Neurology, 2003, 23, 423-434.	0.5	16
229	Compression of Liver Parenchyma by A Malignant Hepatic Cyst: A Previously Unreported Manifestation of Metastatic Gastric Cancer. American Journal of Gastroenterology, 2003, 98, 1211-1213.	0.2	0
230	Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. Clinical Science, 2003, 104, 503-508.	1.8	58
231	Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension. Clinical Science, 2003, 104, 649-654.	1.8	12
232	Pheochromocytoma: Rediscovery as a Catecholamine-Metabolizing Tumor. Endocrine Pathology, 2003, 14, 193-212.	5.2	6
233	Catecholamines and stress. Endocrine Regulations, 2003, 37, 69-80.	0.5	84
234	Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning. Journal of Nuclear Medicine, 2003, 44, 1599-603.	2.8	24

#	Article	IF	CITATIONS
235	Local Sympathetic Denervation in Painful Diabetic Neuropathy. Diabetes, 2002, 51, 3545-3553.	0.3	35
236	Catechol-O-Methyltransferase and Blood Pressure in Humans. Circulation, 2002, 106, 460-465.	1.6	24
237	Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes. Circulation, 2002, 106, 2358-2365.	1.6	96
238	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
239	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119-125.	1.8	23
240	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119.	1.8	26
241	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157.	1.2	41
242	Allostasis, Homeostats, and the Nature of Stress. Stress, 2002, 5, 55-58.	0.8	262
243	Exaggerated Adrenomedullary Response to Immobilization in Mice with Targeted Disruption of the Serotonin Transporter Gene. Endocrinology, 2002, 143, 4520-4526.	1.4	113
244	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	1.8	60
245	Meta-analysis of nonselective versus beta-1 adrenoceptor-selective blockade in prevention of tilt-induced neurocardiogenic syncope. American Journal of Cardiology, 2002, 89, 1319-1321.	0.7	29
246	Children's time of day preference: age, gender and ethnic differences. Personality and Individual Differences, 2002, 33, 1083-1090.	1.6	138
247	Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. Neuropsychopharmacology, 2002, 27, 293-300.	2.8	24
248	Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Annals of Neurology, 2002, 52, 220-223.	2.8	93
249	Kinetic model for the fate of 6-[18 F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 38-49.	1.4	16
250	Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clinical Autonomic Research, 2002, 12, 281-285.	1.4	49
251	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clinical Autonomic Research, 2002, 12, 13-19.	1.4	10
252	Catecholamine Phenotyping: Clues to the Diagnosis, Treatment, and Pathophysiology of Neurogenetic Disorders. Journal of Neurochemistry, 2002, 67, 1781-1790.	2.1	11

#	Article	IF	CITATIONS
253	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119-25.	1.8	10
254	Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men. Life Sciences, 2001, 68, 1889-1898.	2.0	21
255	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	2.0	512
256	Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease. Clinical Autonomic Research, 2001, 11, 341-342.	1.4	16
257	Adrenergic and Endothelin B Receptor-Dependent Hypertension in Dopamine Receptor Type-2 Knockout Mice. Hypertension, 2001, 38, 303-308.	1.3	64
258	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
259	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	1.3	215
260	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649.	3.0	83
261	A "Pheo―Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	1.8	51
262	Sympathetic Neurocirculatory Failure in Parkinson Disease: Evidence for an Etiologic Role of α-Synuclein. Annals of Internal Medicine, 2001, 135, 1010.	2.0	28
263	The wisdom of the body revisited: the adrenomedullary response to mild core hypothermia in humans. Endocrine Regulations, 2001, 35, 3-7.	0.5	9
264	Estimation of striatal dopamine spillover and metabolism in vivo. NeuroReport, 2000, 11, 3367-3373.	0.6	12
265	Sympathetic innervation and function in reflex sympathetic dystrophy. Annals of Neurology, 2000, 48, 49-59.	2.8	56
266	Relative contribution of core and skin temperatures to thermal comfort in humans. Journal of Thermal Biology, 2000, 25, 147-150.	1.1	96
267	A new sign of sympathetic neurocirculatory failure: premature ventricular contraction as a "one-beat Valsalva maneuver― Clinical Autonomic Research, 2000, 10, 63-67.	1.4	9
268	Noninvasive detection of sympathetic neurocirculatory failure. Clinical Autonomic Research, 2000, 10, 285-291.	1.4	61
269	Age-related thermoregulatory differences during core cooling in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R349-R354.	0.9	130
270	THE EFFECT OF DOCARPAMINE, A DOPAMINE PRO-DRUG, ON BLOOD PRESSURE AND CATECHOLAMINE LEVELS IN SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Hypertension, 2000, 22, 419-429.	0.5	9

#	Article	IF	CITATIONS
271	Cardiac Sympathetic Denervation in Parkinson Disease. Annals of Internal Medicine, 2000, 133, 338.	2.0	312
272	Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone- Deficient Mice ¹ . Endocrinology, 2000, 141, 1142-1150.	1.4	78
273	Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2000, 35, 1867-1873.	1.2	43
274	Relative contribution of core and cutaneous temperatures to thermal comfort and autonomic responses in humans. Journal of Applied Physiology, 1999, 86, 1588-1593.	1.2	266
275	Stimulation of the paraventricular nucleus modulates firing of neurons in the nucleus of the solitary tract. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 277, R403-R411.	0.9	26
276	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel–Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	13.9	335
277	A Test of the "Epinephrine Hypothesis―in Humans. Hypertension, 1999, 33, 36-43.	1.3	20
278	Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats. Neurochemical Research, 1999, 24, 25-32.	1.6	21
279	Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects. American Journal of Cardiology, 1999, 84, 316-320.	0.7	26
280	α2-Adrenoceptor-mediated restraint of norepinephrine synthesis, release, and turnover during immobilization in rats. Brain Research, 1999, 826, 243-252.	1.1	27
281	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology, 1999, 20, 29-34.	2.8	56
282	Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biological Psychiatry, 1999, 46, 756-765.	0.7	95
283	Sources and Physiological Significance of Plasma Dopamine Sulfate. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2523-2531.	1.8	95
284	Renal Effects of L-DOPA in Heart Failure. Journal of Cardiovascular Pharmacology, 1999, 33, 922-928.	0.8	10
285	Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Movement Disorders, 1998, 13, 522-528.	2.2	20
286	Dopamine Biosynthesis Is Selectively Abolished in Substantia Nigra/Ventral Tegmental Area but Not in Hypothalamic Neurons in Mice with Targeted Disruption of the Nurr1 Gene. Molecular and Cellular Neurosciences, 1998, 11, 36-46.	1.0	268
287	The Sympathetic Nervous and the Adrenomedullary Hormonal Systems: Differential Responses to Stressors. Journal of Musculoskeletal Pain, 1998, 6, 63-68.	0.3	1
288	Haemodynamic actions of insulin. Current Opinion in Nephrology and Hypertension, 1998, 7, 99-106.	1.0	10

#	Article	IF	CITATIONS
289	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1247-R1255.	0.9	119
290	Modulation of Rat Rotational Behavior by Direct Gene Transfer of Constitutively Active Protein Kinase C into Nigrostriatal Neurons. Journal of Neuroscience, 1998, 18, 4119-4132.	1.7	43
291	Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R165-R173.	0.9	25
292	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122.	0.8	15
293	Dopamine β-Hydroxylase Deficiency Associated with Mutations in a Copper Transporter Gene. Advances in Pharmacology, 1997, 42, 66-68.	1.2	15
294	Novel Catecholaminergic Systems. Advances in Pharmacology, 1997, 42, 819-824.	1.2	0
295	Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. Advances in Pharmacology, 1997, 42, 561-564.	1.2	27
296	Sympathetic Cardioneuropathy in Dysautonomias. New England Journal of Medicine, 1997, 336, 696-702.	13.9	309
297	On the Dialectic Between Molecular Biology and Integrative Physiology: Toward a New Medical Science. Perspectives in Biology and Medicine, 1997, 40, 505-515.	0.3	7
298	Gender Differences in Brain Metabolic and Plasma Catecholamine Responses to Alpha2-Adrenoceptor Blockade. Neuropsychopharmacology, 1997, 16, 298-310.	2.8	31
299	Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology, 1997, 97, 38-45.	1.2	28
300	Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 1996, 48, 957-962.	0.5	65
301	Effects of Continuous and Intermittent Cold (SART) Stress on Sympathoadrenal System Activity in Rats. Journal of Neuroendocrinology, 1996, 8, 65-72.	1.2	26
302	Differential Effects of Low- and High-Intensity Lower Body Negative Pressure on Noradrenaline and Adrenaline Kinetics in Humans. Clinical Science, 1996, 90, 337-343.	1.8	21
303	Successful Early Copper Therapy in Menkes Disease Associated with a Mutant Transcript Containing a Small In-Frame Deletion. Biochemical and Molecular Medicine, 1996, 57, 37-46.	1.5	61
304	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152.	1.1	11
305	Plasma sulfoconjugated dopamine levels are normal in patients with autonomic failure. Translational Research, 1996, 128, 488-491.	2.4	7
306	Interrelations between Sympathoadrenal System andHypothalamo-Pituitary-Adrenocortical/Thyroid Systemsin Rats Exposed to Cold Stress. Journal of Neuroendocrinology, 1996, 8, 533-541.	1.2	64

#	Article	IF	CITATIONS
307	Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. Journal of Neuroendocrinology, 1996, 8, 543-551.	1.2	31
308	Cardiac Sympathetic Nerve Function in Congestive Heart Failure. Circulation, 1996, 93, 1667-1676.	1.6	376
309	Prothrombotic Effects of Environmental Stress. Psychosomatic Medicine, 1995, 57, 592-599.	1.3	63
310	Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. American Journal of Cardiology, 1995, 76, 125-130.	0.7	131
311	Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Annals of Neurology, 1995, 38, 921-928.	2.8	74
312	Glucocorticoid-induced sympathoinhibition in humans. Clinical Pharmacology and Therapeutics, 1995, 58, 90-98.	2.3	48
313	Functional α3-glycine receptors in rat adrenal. European Journal of Pharmacology, 1995, 288, 399-401.	2.7	8
314	Coping responses to HIVâ€l serostatus notification predict concurrent and prospective immunologic status. Clinical Psychology and Psychotherapy, 1995, 2, 234-248.	1.4	31
315	Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. Frontiers in Neuroendocrinology, 1995, 16, 89-150.	2.5	348
316	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. Brain Research, 1995, 688, 242-246.	1.1	92
317	Is There a Third Peripheral Catecholaminergic System? Endogenous Dopamine as an Autocrine/ Paracrine Substance Derived from Plasma DOPA and Inactivated by Conjugation. Hypertension Research, 1995, 18, S93-S99.	1.5	69
318	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. Journal of the Autonomic Nervous System, 1995, 54, 104-112.	1.9	2
319	Effects of Various Stressors on In Vivo Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and on the Pituitary-Adrenocortical Axis. Annals of the New York Academy of Sciences, 1995, 771, 115-130.	1.8	141
320	Clinical Assessment of Sympathetic Responses to Stress. Annals of the New York Academy of Sciences, 1995, 771, 570-593.	1.8	22
321	Monoaminergic Effects of Folinic Acid, <scp>l</scp> â€ĐOPA, and 5â€Hydroxytryptophan in Dihydropteridine Reductase Deficiency. Journal of Neurochemistry, 1995, 64, 2810-2813.	2.1	14
322	The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy. Neuropsychopharmacology, 1994, 10, 1-7.	2.8	125
323	Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine. Patient Education and Counseling, 1994, 24, 261-266.	1.0	35
324	Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1994, 653, 131-138.	1.7	213

#	Article	IF	CITATIONS
325	Prostate cancer screening: Role of digital rectal examination and prostate-specific antigen. Annals of Surgical Oncology, 1994, 1, 117-120.	0.7	28
326	Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nature Genetics, 1994, 8, 195-202.	9.4	244
327	Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity. Kidney International, 1994, 45, 556-560.	2.6	74
328	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 1994, 50, 93-107.	1.9	39
329	On the existence of functional beta-adrenoceptors on vascular sympathetic nerve endings in the human forearm. Journal of Hypertension, 1994, 12, 681???690.	0.3	5
330	Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Annals of Neurology, 1993, 33, 171-175.	2.8	101
331	Human recombinant interferon-?SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Research and Treatment, 1993, 25, 141-150.	1.1	11
332	Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. Journal of Neuroendocrinology, 1993, 5, 475-486.	1.2	30
333	Plasma catecholamine, renin activity, and ACTH responses to the serotonin receptor agonist DOI in juvenile spontaneously hypertensive rats. Life Sciences, 1993, 53, 1573-1582.	2.0	7
334	Glycine stimulates striatal dopamine release in conscious rats. British Journal of Pharmacology, 1993, 110, 50-53.	2.7	37
335	Positron emission tomographic imaging of cardiac sympathetic Innervation using 6-[18 F]Fluorodopamine: Initial findings in humans. Journal of the American College of Cardiology, 1993, 22, 1961-1971.	1.2	106
336	Oral Yohimbine Increases Blood Pressure and Sympathetic Nervous Outflow in Hypertensive Patients. Journal of Cardiovascular Pharmacology, 1993, 22, 22-26.	0.8	112
337	Inhibition of Peritoneal Tumor-Cell Implantation: Model for Laparoscopic Cancer Surgery. Journal of Endourology, 1993, 7, 237-241.	1.1	68
338	Induction of reversible growth retardation and growth hormone deficiency by blockade of norepinephrine synthesis in the rat. European Journal of Endocrinology, 1993, 129, 554-558.	1.9	1
339	Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. Neuroendocrinology, 1993, 57, 626-633.	1.2	64
340	Laparoscopic Correction of Vesicoureteral Reflux. Journal of Urology, 1993, 150, 748-751.	0.2	134
341	Derivation of Urinary Dopamine from Plasma Dihydroxyphenylalanine in Humans. Clinical Science, 1993, 84, 549-557.	1.8	86
342	Sympathoadrenal contribution to plasma dopa (3,4-dihydroxyphenylalanine) in rats. Clinical Science, 1992, 83, 65-74.	1.8	28

#	Article	IF	CITATIONS
343	Cerebrospinal Fluid and Serum Levels of DOPA, Catechols, and Monoamine Metabolites in Patients with Epilepsy. Epilepsia, 1992, 33, 263-270.	2.6	38
344	Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biological Psychiatry, 1992, 32, 880-890.	0.7	46
345	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. Brain Research, 1992, 589, 91-96.	1.1	110
346	A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Investigational New Drugs, 1992, 10, 107-112.	1.2	4
347	Effects of Handling or Immobilization on Plasma Levels of 3,4-Dihydroxyphenylalanine, Catecholamines, and Metabolites in Rats. Journal of Neurochemistry, 1992, 58, 2296-2302.	2.1	65
348	Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man. Clinical Autonomic Research, 1992, 2, 359-366.	1.4	24
349	Simultaneous measurement of plasma and brain extracellular fluid concentrations of catechols after yohimbine administration in rats. Brain Research, 1991, 542, 8-14.	1.1	47
350	Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. Journal of the Autonomic Nervous System, 1991, 34, 17-35.	1.9	46
351	Sympathoadrenal excitation and inhibition by lower brainstem stimulation in cats. Journal of the Autonomic Nervous System, 1991, 33, 35-46.	1.9	25
352	Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. Journal of the Autonomic Nervous System, 1991, 35, 169-174.	1.9	3
353	Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma. Gynecologic Oncology, 1991, 41, 22-27.	0.6	8
354	Advances in drug delivery and targeting. Current Opinion in Oncology, 1991, 3, 1096-1104.	1.1	8
355	Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. Journal of Hypertension, 1991, 9, 417-423.	0.3	37
356	Method for measuring endogenous 3-O-methyldopa in urine and plasma. Biomedical Applications, 1991, 568, 45-54.	1.7	3
357	Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation, 1991, 9, 35-48.	0.6	15
358	Sex, Handedness and Allergy: Are They Related to Academic Giftedness?. Journal for the Education of the Cifted, 1991, 14, 412-422.	0.5	9
359	Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-î±2. Breast Cancer Research and Treatment, 1990, 15, 95-101.	1.1	18
360	Neurotransmitters and stress. Biofeedback and Self-regulation, 1990, 15, 243-271.	0.3	14

#	Article	IF	CITATIONS
361	Differences in the Neuronal Removal of Circulating Epinephrine and Norepinephrine. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1710-1720.	1.8	43
362	Altered norepinephrine regulation in bulimia: Effects of pharmacological challenge with isoproterenol. Psychiatry Research, 1990, 33, 1-10.	1.7	23
363	Prolonged changes in plasma concentrations of catecholamine metabolites following a single infusion of an MPTP analog. Life Sciences, 1990, 47, 1895-1901.	2.0	3
364	Epinephrine Suppresses Stress-Induced Increases in Plasma Immunoreactive β-Endorphin in Humans. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 546-551.	1.8	16
365	Plasma Dihydroxyphenylalanine and Total Body and Regional Noradrenergic Activity in Humans. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 247-255.	1.8	45
366	Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Annals of Neurology, 1989, 26, 558-563.	2.8	164
367	Plasma levels of catechols during reflexive changes in sympathetic nerve activity. Neurochemical Research, 1989, 14, 523-531.	1.6	16
368	Plasma levels of catechols after fasting in intact or adrenal-demedullated rats. Journal of the Autonomic Nervous System, 1989, 26, 181-184.	1.9	7
369	Skin color, aging, and plasma l-dopa levels. Journal of the Autonomic Nervous System, 1989, 26, 261-263.	1.9	14
370	Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clinical Science, 1989, 76, 171-182.	1.8	63
371	Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans. Clinical Science, 1989, 76, 517-522.	1.8	64
372	The Role of Interferon in Cancer Therapy: A Current Perspective. Ca-A Cancer Journal for Clinicians, 1988, 38, 258-277.	157.7	89
373	Simultaneous determination of endogenous catechols and exogenous 2- and 6-fluorinated catechols in tissue and plasma using liquid chromatography with electrochemical detection. Biomedical Applications, 1988, 431, 156-162.	1.7	9
374	Catecholamines and their metabolites. Biomedical Applications, 1988, 429, 177-233.	1.7	156
375	Species-dependent differences in recovery of 3,4-dihydroxybenzylamine in assays of plasma catecholamines. Biomedical Applications, 1988, 430, 123-127.	1.7	7
376	Source and Physiological Significance of Plasma 3,4-Dihydroxyphenylalanine in the Rat. Journal of Neurochemistry, 1988, 51, 1204-1213.	2.1	42
377	Levels of Catechols in Epileptogenic and Nonepileptogenic Regions of the Human Brain. Journal of Neurochemistry, 1988, 50, 225-229.	2.1	55
378	Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. Journal of the Autonomic Nervous System, 1988, 24, 1-14.	1.9	96

#	Article	IF	CITATIONS
379	Sympathoadrenomedullary hyper-responsiveness to yohimbine in juvenile spontaneously hypertensive rats. Life Sciences, 1988, 43, 1063-1068.	2.0	23
380	Sympathoadrenomedullary Inhibition by Chronic Glucocorticoid Treatment in Conscious Rats. Endocrinology, 1988, 123, 2585-2590.	1.4	42
381	Contributions of Benzodiazepines to Cancer Therapy. Cancer Investigation, 1988, 6, 103-111.	0.6	20
382	Down-regulation of an abundant cellular protein associated with tumor progression. Carcinogenesis, 1988, 9, 2129-2132.	1.3	0
383	Steady-state dopamine clearance in critically ill infants and children. Critical Care Medicine, 1988, 16, 217-220.	0.4	60
384	Antihypertensive Therapy with Ketanserin. Journal of Cardiovascular Pharmacology, 1988, 12, 384-389.	0.8	1
385	The Doctor's Dilemma (The Nurse's Waterloo). Cancer Investigation, 1988, 6, 361-363.	0.6	0
386	Derivation of urinary dopamine from plasma dopa. Clinical Science, 1988, 75, 515-520.	1.8	61
387	Neuronal Source of Plasma Dihydroxyphenylalanine. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 856-861.	1.8	88
388	Responses of the Hypothalamic-Pituitary-Adrenal and Renin-Angiotensin Axes and the Sympathetic System During Controlled Surgical and Anesthetic Stress. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 986-994.	1.8	257
389	Reversibility of Catecholamine-Induced Dilated Cardiomyopathy in a Child with a Pheochromocytoma. New England Journal of Medicine, 1987, 316, 793-797.	13.9	203
390	Dietary Salt Intake and the Clonidine Suppression Test. Journal of Clinical Pharmacology, 1987, 27, 199-205.	1.0	4
391	THE ROLE OF ATRIAL NATRIURETIC PEPTIDE IN CONGENITAL HEART DISEASE. Critical Care Medicine, 1987, 15, 413.	0.4	0
392	NEONATOLOGY FRIDAY, MAY 29TH, 1987 SOUTH BALLROOM 10. Critical Care Medicine, 1987, 15, 436.	0.4	1
393	Corticotropin-releasing factor (CRF) produces analgesia in humans and rats. Brain Research, 1987, 422, 154-157.	1.1	95
394	Catecholamine-glucocorticoid interactions during surgical stress. Journal of Surgical Research, 1987, 43, 539-545.	0.8	64
395	Stress-induced activation of the sympathetic nervous system. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 253-278.	1.0	85
396	Angiotensin II increases cytosolic calcium and stimulates catecholamine release in cultured bovine adrenomedullary cells. Cell Calcium, 1987, 8, 315-325.	1.1	49

#	Article	IF	CITATIONS
397	Effect of Ganglion Blockade on Cerebrospinal Fluid Norepinephrine. Journal of Neurochemistry, 1987, 49, 1484-1490.	2.1	36
398	Indices of sympathetic vascular innervation in sympathectomized patients. Journal of the Autonomic Nervous System, 1986, 15, 309-318.	1.9	31
399	Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma. Annals of Internal Medicine, 1986, 105, 887.	2.0	49
400	Naloxone, fentanyl, and diazepam modify plasma beta-endorphin levels during surgery. Clinical Pharmacology and Therapeutics, 1986, 40, 165-171.	2.3	62
401	Plasma catecholamine and hemodynamic responses during isoproterenol infusions in humans. Clinical Pharmacology and Therapeutics, 1986, 40, 233-238.	2.3	40
402	Functional corticotropin releasing factor receptors in the primate peripheral sympathetic nervous system. Nature, 1986, 319, 147-150.	13.7	171
403	Endocrine, Renal, and Hemodynamic Responses to Graded Dopamine Infusions in Normal Men. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 821-826.	1.8	55
404	Clonidine Suppression Testing in Essential Hypertension. Annals of Internal Medicine, 1985, 102, 42.	2.0	68
405	Decreased sympathetic neuronal uptake in idiopathic orthostatic hypotension. Annals of Neurology, 1985, 18, 48-53.	2.8	31
406	Morphine Inhibits the Pituitary-Adrenal Response to Ovine Corticotropin-Releasing Hormone in Normal Subjects*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 891-895.	1.8	109
407	Neural circulatory control in the hyperdynamic circulatory state syndrome. American Heart Journal, 1985, 109, 387-390.	1.2	7
408	Changes in coagulation parameters with exercise in patients with classic hemophilia. American Journal of Hematology, 1984, 16, 227-233.	2.0	39
409	Dihydrocaffeic acid: a common contaminant in the liquid chromatographic-electrochemical measurement of plasma catecholamines in man. Biomedical Applications, 1984, 311, 148-153.	1.7	49
410	Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology, 1984, 84, 200-204.	1.5	45
411	Pressor and depressor responses after cholinergic blockade in humans. American Heart Journal, 1984, 107, 974-979.	1.2	22
412	Modified sample preparation for high-performance liquid chromatographic—electrochemical assay of urinary catecholamines. Biomedical Applications, 1983, 275, 174-177.	1.7	22
413	Applied developmental psychology: Problems and prospects for an emerging discipline. Journal of Applied Developmental Psychology, 1983, 4, 341-348.	0.8	9
414	Plasma and urinary catechllamines during the human ovulatory cycle. American Journal of Obstetrics and Gynecology, 1983, 146, 824-829.	0.7	86

#	Article	IF	CITATIONS
415	Circulatory control mechanisms in vasodepressor syncope. American Heart Journal, 1982, 104, 1071-1075.	1.2	105
416	Validity of liquid chromatography with electrochemical detection for measuring dopamine in human plasma. Clinica Chimica Acta, 1981, 117, 113-120.	0.5	31
417	Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. American Journal of Cardiology, 1981, 48, 1147-1154.	0.7	136
418	II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sciences, 1981, 28, 467-475.	2.0	450
419	Plasma catecholamines and renin during operant blood pressure conditioning in baboons. Physiology and Behavior, 1981, 26, 33-37.	1.0	14
420	Frequency and the conference of referential validity. Journal of Verbal Learning and Verbal Behavior, 1977, 16, 107-112.	3.8	589
421	Biofeedback heart rate training during exercise. Biofeedback and Self-regulation, 1977, 2, 107-125.	0.3	73
422	Cognition of arousal and actual arousal as determinants of emotion Journal of Personality and Social Psychology, 1972, 21, 41-51.	2.6	66
423	Sources and Physiological Significance of Plasma Dopamine Sulfate. , 0, .		20
424	'Sick But Not Dead': Multiple Denervation-Independent Abnormalities of Myocardial Noradrenergic Function in Lewy Body Diseases. SSRN Electronic Journal, 0, , .	0.4	1